Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma
Journal of Nuclear Medicine · 2024-04 · 65 (4) · 586-592
DOI: 10.2967/jnumed.123.266766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 29.02.2024. Verfasst von Fanching Lin und 14 weiteren Autor:innen. Beteiligte Einrichtung: RayzeBio, Inc., San Diego, California; and. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Glypican-3 (GPC3) is a membrane-associated glycoprotein that is significantly upregulated in hepatocellular carcinomas (HCC) with minimal to no expression in normal tissues. The differential expression of GPC3 between tumor and normal tissues provides an opportunity for targeted radiopharmaceutical therapy to treat HCC, a leading cause of cancer-related deaths worldwide.
Methods
DOTA-RYZ-GPC3 (RAYZ-8009) comprises a novel macrocyclic peptide binder to GPC3, a linker, and a chelator that can be complexed with different radioisotopes. The binding affinity was determined by surface plasma resonance and radioligand binding assays. Target-mediated cellular internalization was radiometrically measured at multiple time points. In vivo biodistribution, monotherapy, and combination treatments with 177Lu or 225Ac were performed on HCC xenografts.
Results
RAYZ-8009 showed high binding affinity to GPC3 protein of human, mouse, canine, and cynomolgus monkey origins and no binding to other glypican family members. Potent cellular binding was confirmed in GPC3-positive HepG2 cells and was not affected by isotope switching. RAYZ-8009 achieved efficient internalization on binding to HepG2 cells. Biodistribution study of 177Lu-RAYZ-8009 showed sustained tumor uptake and fast renal clearance, with minimal or no uptake in other normal tissues. Tumor-specific uptake was also demonstrated in orthotopic HCC tumors, with no uptake in surrounding liver tissue. Therapeutically, significant and durable tumor regression and survival benefit were achieved with 177Lu- and 225Ac-labeled RAYZ-8009, as single agents and in combination with lenvatinib, in GPC3-positive HCC xenografts.
Conclusion
Preclinical in vitro and in vivo data demonstrate the potential of RAYZ-8009 as a theranostic agent for the treatment of patients with GPC3-positive HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RayzeBio, Inc., San Diego, California; and.
- PeptiDream Inc., Kanagawa, Japan.
- RayzeBio, Inc., San Diego, California; and gli@rayzebio.com.
Zitieren
APA
Lin, F., Clift, R., Ehara, T., Yanagida, H., Horton, S., Noncovich, A., Guest, M., Kim, D., Salvador, K., Richardson, S., Miller, T., Han, G., Bhat, A., Song, K., & Li, G. (2024). Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. Journal of Nuclear Medicine, 65(4), 586-592. https://doi.org/10.2967/jnumed.123.266766
Vancouver
Lin F, Clift R, Ehara T, Yanagida H, Horton S, Noncovich A, et al. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. Journal of Nuclear Medicine. 2024;65(4):586-592. doi:10.2967/jnumed.123.266766
BibTeX
@article{Lin2024,
author = {Lin, Fanching and Clift, Renee and Ehara, Takeru and Yanagida, Hayato and Horton, Steven and Noncovich, Alain and Guest, Matt and Kim, Daniel and Salvador, Katrina and Richardson, Samantha and Miller, Terra and Han, Guangzhou and Bhat, Abhijit and Song, Kenneth and Li, Gary},
title = {Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {4},
pages = {586--592},
doi = {10.2967/jnumed.123.266766}
}
EUVIMED